For the quarter ending 2026-03-31, GALT had -$3,609K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,046 | -5,500 | -8,184 | -17,152 |
| Amortization of right to use asset | - | 53 | - | - |
| Stock-based compensation expense | 686 | 195 | 496 | 968 |
| Amortization of right to use lease asset | 0 | - | 0 | 12 |
| Non-cash interest expense | 156 | 183 | 215 | 696 |
| Change in fair value of derivative liabilities | -983 | 220 | 2,205 | 1,121 |
| Prepaid expenses and other assets | -140 | 479 | -467 | -428 |
| Accounts payable, accrued expenses and other liabilities | -662 | -2,458 | -345 | -3,239 |
| Accrued interest on convertible debt - related party | 1,831 | 1,756 | 1,604 | 2,875 |
| Net cash from operating activities | -3,866 | -6,042 | -3,542 | -14,291 |
| Net proceeds from exercise of common stock options and warrants | - | 1,073 | 443 | 724 |
| Net proceeds from issuance of common stock | - | 1,164 | 853 | 1,218 |
| Net cash from investing activities | - | 0 | - | - |
| Net proceeds from exercise of stock options | 257 | 10,000 | 0 | 11,000 |
| Net cash flows from financing activities | 257 | 12,237 | 1,296 | 12,942 |
| Net decrease in cash and cash equivalents | -3,609 | 6,195 | -2,246 | -1,349 |
| Cash and cash equivalents, beginning of period | 17,720 | 11,525 | 15,120 | - |
| Cash and cash equivalents, end of period | 14,111 | 17,720 | 11,525 | - |
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)